结肠癌患者肿瘤组织及外周血ICAM-1和VCAM-1表达的研究

Study of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expressions in cancer tissue and serum of patients with colon cancer

目的:检测结肠癌患者肿瘤组织中细胞间粘附分子-1(intercellular adhension molecular-1,I-CAM-1)和血管细胞粘附分子-1(vascular cell adhesion molecular-1,VCAM-1)的表达,同时测定血清中可溶性ICAM-1(sICAM-l)和可溶性VCAM-1(sVCAM-1)水平,探讨二者与结肠癌生物学特性及预后的关系。方法:应用免疫组化SP法对32例结肠癌组织、17例溃疡性结肠炎组织和21例正常结肠组织标本进行ICAM-1与VCAM-1表达检测,分析其与结肠癌临床病理指标的关系。ELISA法检测结肠癌患者手术前后外周血sICAM-1和sVCAM-1含量,分析治疗前后水平的变化。结果:结肠癌组织ICAM-1和VCAM-1的阳性表达率显著高于溃疡性结肠炎组织(P<0.05)及正常结肠组织(P<0.01),其表达水平与患者年龄、性别、肿瘤大小和病理学分级无关(P>0.05),与肿瘤分期及有无远处转移有关(P<0.05);结肠癌患者外周血sICAM-1和sVCAM-1水平明显高于溃疡性结肠炎患者(P<0.05)及正常对照组(P<0.01),结肠癌患者术后1周sICAM-1及sVCAM-1水平明显下降(P<0.01,P<0.01)。结论:结肠癌患者肿瘤组织及外周血ICAM-1和VCAM-1的表达可能与结肠癌的浸润转移有关;sICAM-1、sVCAM-1的检测可能成为监测结肠癌病情进展和评价治疗效果的有价值指标。

Objectives： To detect the expressions of ICAM-1, VCAM-1 in colon cancer tissues and to measure the serum soluble intercellular adhesion molecular-Ⅰ （sICAM-Ⅰ） and soluble vascular cell adhesion molecular-1 （sVCAM-Ⅰ）. Methods： Specimens from 32 colon cancer patients, 17 ulcerative colitis patients, 21 normal tissues were observed by immunohistochemistry. ELSIA technique was used to measure serum concentration of sICAM-1 and sVCAM-1 before and post operation in colon cancer patients. Results： The expressions of ICAM-1 and VCAM-Ⅰ in colon cancer tissues were significantly higher than those in ulcerative colitis tissues （P〈0.05） and in normal control group （P〈0.01）. Their expressions were not related to age, sex, tumor size and pathological grade （P〉0.05）, but had significantly statistic difference between TNM stage and metastasis （P〈0. 01）. The level of sICAM-1 and sVCAM-1 in serum of colon cancer patients were significantly higher than those in ulcerative colitis patients （P〈0.05） and in health control group （P〈0.01）. The levels in colon cancer 7 days postoperatively decreased significantly （P〈0.01）. Conclusions： The expressions of ICAM-1and VCAM-1 may be related with invasion, metastasis of colon cancer. The measurement of serum sICAM-1 and sVCAM-1 may be valuable markers to evaluate the progression, therapeutic evaluation for patients with colon cancer.